



IMPORTANT Information
US Special Access Protocol for Trasyol[®] (aprotinin injection)

January 2, 2008

Today the U.S. Food and Drug Administration (FDA) has approved a special access protocol for Trasyol that will allow physicians access to aprotinin during the temporary marketing suspension pending receipt and evaluation of final data from the Canadian-based BART trial.

Bayer's U.S. special access protocol (under a treatment IND) is a non-randomized, open-label treatment program. The program will provide aprotinin for treatment of surgical patients undergoing coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass (CPB) who are at increased risk of bleeding and transfusion when, in the opinion of the treating physician, the patients require it, there is no acceptable alternative therapy, and when there is a clearly favorable benefit-risk for the drug in that individual patient.

This study is open to any licensed U.S. cardiovascular surgeon or anesthesiologist. A participating physician will be considered to be an Investigator and must complete a 1572 form listing all participating staff at his/her facility. Additionally, under the study protocol, participating investigators will be assumed to be performing appropriate surgical/medical procedures according to the local standard of care.

On November 5, 2007, after consultation with various health authorities around the world, Bayer announced that it would temporarily suspend worldwide marketing of Trasyol (aprotinin injection) until final results from the BART trial are compiled, received, and evaluated. Shipments of Trasyol from Bayer distribution centers were halted that day.

Bayer has worked diligently with the FDA to swiftly institute this program by which Trasyol could remain available for U.S. physician use for treatment of certain patients under specific guidelines during the temporary suspension. Bayer is also working with health authorities on similar programs in other markets.

Once the complete BART dataset has been compiled, received and evaluated, Bayer will work with the FDA and other health authorities to evaluate whether these data have any impact on the positive benefit-risk assessment for Trasyol. At that time the temporary marketing suspension will be reevaluated. Bayer will

continue to be in close contact with the FDA and other health authorities and, in conjunction with them, will continue to seek information from the BART investigators about the progress of the final data collection and analysis process.

While it is Bayer's intention to continue the program until aprotinin is once again commercially available, the protocol may be discontinued at any time if, for example, data become available from the BART study that change the risk/benefit assessment. The protocol may also be discontinued at any site if the Investigator fails to follow the protocol with regard to patient selection and consent, drug dosing, and safety reporting requirements.

Bayer believes that the totality of the available data continue to support a favorable risk-benefit profile for Trasylol when used according to labeling.

A description of the study protocol and instructions regarding how to participate and/or obtain further information follow.

Study Title:	Aprotinin Special Access Protocol: An Open Label, Non-Comparative Treatment Protocol for the Use of Aprotinin in Patients Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass Who Are at Increased Risk of Blood Loss and Transfusion
Objective	To provide access to aprotinin for treatment of surgical patients having CABG surgery requiring CPB and at increased risk of bleeding and blood transfusion, and, in the opinion of the treating physician, there is no acceptable alternative therapy. This is a limited access program that will allow physicians access to aprotinin during the temporary marketing suspension for patients who, in their medical judgment, require it, and when there is a clearly favorable benefit-risk for the drug in that individual patient.
Bayer Study Number	13087
Design:	Open-label, non-comparative treatment protocol; all patients will receive aprotinin.
Study Drug Dose & Administration	Aprotinin will be administered as described in the Package Insert. The dose will be either the half dose or the full dose based on the investigator's discretion.
Countries:	US only
Inclusion Criteria:	<ul style="list-style-type: none"> • Patients 18 years of age and older. • Patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. These patients may include the following: <ul style="list-style-type: none"> - Patients receiving preoperative antithrombotic drugs (e.g., clopidogrel, aspirin), - Patients undergoing repeat CABG or complex CABG

	<p>procedures,</p> <ul style="list-style-type: none"> - Patients undergoing urgent or emergent CABG procedures, - Patients who refuse to receive allogeneic blood products for religious or other reasons, - Patients undergoing primary CABG with advanced age or multiple comorbidities such as preoperative anemia, coagulopathies, diabetes mellitus, and peripheral vascular disease. <ul style="list-style-type: none"> • The physician has determined that no acceptable alternative comparable therapy is available for the patient and that there is a clearly favorable benefit-risk for the drug in that individual patient. • Documented, signed, dated informed consent obtained prior to entry into the study.
Exclusion Criteria:	<ul style="list-style-type: none"> • Patients with a known or suspected previous aprotinin exposure during the last 12 months. Aprotinin may also be a component of some fibrin sealant products, and the use of these products should be considered when evaluating previous aprotinin exposure. • Patients with a known or suspected allergy to aprotinin.
Reimbursement:	Patients, investigators, and institutions will not be reimbursed for their participation. Aprotinin will be supplied free of charge.
Participation Requirements:	Cardiovascular surgeons or anesthesiologists who wish to become investigators must fulfill all Institutional Review Board (IRB) and Good Clinical Practice (GCP) requirements, complete an FDA 1572 Form, obtain patient informed consent, collect required information on electronic case report forms (CRFs), undergo an initiation visit, agree to contractual requirements, and have internet access.

How to Participate and/or Obtain Further Information

If you are a US cardiovascular surgeon or anesthesiologist and want to become an investigator, print out the form below, fill in the information, and fax the completed form to Kathy Gahagan at (973) 487-2660.

US cardiovascular surgeons, anesthesiologists and hospital pharmacists seeking additional information may contact Bayer Medical Communications at (888) 842-2937 [select option 3, then press 4 for Trasylol].

13087 Contract Information Sheet

The following information is required in order to process clinical agreements.

Principal Investigator:

Name:		Telephone:	
Title:		Fax:	
Address:		Email:	
City/State/Zip:			

Please indicate which category is most appropriate to describe the contract organization:

- Site or Trial Management Organization**
- Single Private Practice location**
- Educational Institution or Hospital**

Name and complete Title of Official Authorized to sign Contracts on behalf of Organization:

Name of Business based on the W9 tax ID number:

Contact Person at Organizational level for issues relating to Contracts and Payments:

Name:		Telephone:	
Title:		Fax:	
Address:		Email:	
City/State/Zip:			

Please print or type the following information and fax this sheet to Bayer:

FAX: (973) 487-2660
Attn: Kathy Gahagan

*If you have any questions about completing this form, please contact:
Kathy Decker at (203) 605-5532*